Bajaj Healthcare: ₹52.71 Cr In, Loan Repaid, Capex Slows

OTHER
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Bajaj Healthcare: ₹52.71 Cr In, Loan Repaid, Capex Slows
Overview

Bajaj Healthcare confirmed its use of funds from a recent fundraising, including ₹52.71 Crores received in Q4 FY26. Total utilization reached ₹173 Crores, primarily for loan repayment, with capital expenditure deployment noted as slow.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Bajaj Healthcare Details Fund Use as ₹52.71 Cr Warrant Funds Arrive

Bajaj Healthcare Ltd. has confirmed the utilization of funds raised through its preferential issue and warrant conversion. The company reported receiving ₹52.71 Crores in the fourth quarter of fiscal year 2026 from the exercise of warrant conversions.

Total Funds Deployed

As of March 31, 2026, Bajaj Healthcare had utilized ₹173 Crores of the total ₹207 Crores raised. These funds were allocated to key areas as per the company's initial plans.

Allocation Breakdown

The deployed capital was primarily directed towards loan repayment, accounting for ₹150 Crores. Additionally, ₹3.16 Crores were allocated to capital expenditure, and ₹19.84 Crores were used for general corporate purposes.

Investor Transparency and Capex Focus

This confirmation provides investors with transparency on fund management, reinforcing confidence in the company's governance. However, the filing highlights a slow pace in capital expenditure deployment, with only ₹3.16 Crores utilized out of an indicated ₹35 Crores for capex. This suggests potential delays or a more gradual timeline for planned expansion or asset upgrades, which remains a watchpoint for investors.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.